Headlines Expert Newsletters Covid-19 Specialties Trending Feeds Videos

PURPOSE Patients with Diffuse Large B-cell Lymphoma (DLBCL) in need of immediate therapy are largely under-represented in clinical trials. The diagnosis-to-treatment interval (DTI) has recently been described as a metric to quantify such patient selection bias, with short DTI being associated with adverse risk factors and inferior outcomes. Here, we characterized the relationships between DTI,...

  • Previous studies had shown short diagnosis to treatment interval (DTI) associated with poor prognosis in DLBCL, which likely contributes to bias in clinical trials. This study shows correlation between elevated ctDNA levels and DTI and that pretreatment ctDNA is associated with other markers of aggressive disease and tumor burden.